

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/06/30	2020/12/31	2020/06/30
<b>Balance Sheet</b>			
<b>Current assets</b>			
Cash and cash equivalents	615,429	291,141	303,907
Current financial assets at amortised cost	1,200	1,200	9,582
Current contract assets	154,956	101,779	61,378
Accounts receivable, net	60,259	66,947	48,468
Accounts receivable due from related parties, net	978	305	9,728
Other receivables	10,159	5,511	181
Current inventories	157,257	84,852	69,750
Prepayments	44,267	23,817	25,253
Other current assets	6,503	958	4,533
<b>Total current assets</b>	<b>1,051,008</b>	<b>576,510</b>	<b>532,780</b>
<b>Non-current assets</b>			
Non-current financial assets at fair value through other comprehensive income	107,190	191,810	226,040
Property, plant and equipment	880,204	690,078	539,690
Right-of-use assets	87,937	96,653	44,840
Intangible assets	59,190	60,641	66,745
Deferred tax assets	82,488	83,450	73,154
Other non-current assets	282,095	53,411	20,716
<b>Total non-current assets</b>	<b>1,499,104</b>	<b>1,176,043</b>	<b>971,185</b>
<b>Total assets</b>	<b>2,550,112</b>	<b>1,752,553</b>	<b>1,503,965</b>
<b>Current liabilities</b>			
Current borrowings	0	100,000	0
Current contract liabilities	106,444	125,904	71,792
Accounts payable	52,832	40,314	31,621
Other payables	227,054	132,326	82,193
Current tax liabilities	2,459	645	0
Current lease liabilities	21,357	24,325	13,936
Other current liabilities	1,083	1,265	1,135
<b>Total current liabilities</b>	<b>411,229</b>	<b>424,779</b>	<b>200,677</b>
<b>Non-current liabilities</b>			
Deferred tax liabilities	4,174	6,681	512
Non-current lease liabilities	66,770	72,282	30,081
Other non-current liabilities	37,608	37,144	36,692
<b>Total non-current liabilities</b>	<b>108,552</b>	<b>116,107</b>	<b>67,285</b>
<b>Total liabilities</b>	<b>519,781</b>	<b>540,886</b>	<b>267,962</b>
<b>Share capital</b>			
Ordinary share	1,532,545	1,282,377	1,279,545
Advance receipts for share capital	2,009	499	0
<b>Total Share Capital</b>	<b>1,534,554</b>	<b>1,282,876</b>	<b>1,279,545</b>
<b>Capital surplus</b>			
Total capital surplus	571,044	53,113	41,931
<b>Retained earnings</b>			
Unappropriated retained earnings (accumulated deficit)	-122,400	-207,233	-193,753
<b>Total retained earnings</b>	<b>-122,400</b>	<b>-207,233</b>	<b>-193,753</b>
<b>Other equity interest</b>			
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	47,133	82,911	108,280
<b>Total other equity interest</b>	<b>47,133</b>	<b>82,911</b>	<b>108,280</b>
<b>Total equity</b>	<b>2,030,331</b>	<b>1,211,667</b>	<b>1,236,003</b>
<b>Total liabilities and equity</b>	<b>2,550,112</b>	<b>1,752,553</b>	<b>1,503,965</b>
Equivalent issue shares of advance receipts for ordinary share	63,700	15,900	0
Number of shares in entity held by entity and by its subsidiaries	0	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/2nd	2020/2nd	2021/01/01To2021/06/30	2020/01/01To2020/06/30
<b>Income Statement</b>				
Total operating revenue	106,733	268,972	398,950	338,833
Total operating costs	132,772	140,032	258,984	201,949
Gross profit (loss) from operations	-26,039	128,940	139,966	136,884
Gross profit (loss) from operations	-26,039	128,940	139,966	136,884
Operating expenses				
Selling expenses	8,490	14,814	18,549	23,578
Administrative expenses	15,408	14,583	33,822	24,391
Research and development expenses	18,398	14,253	39,241	29,224
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	-3,666	3,123	-1,655	3,447
Total operating expenses	38,630	46,773	89,957	80,640
Net operating income (loss)	-64,669	82,167	50,009	56,244
Non-operating income and expenses				
Total interest income	144	722	171	1,324
Total other income	493	1,522	828	2,512
Other gains and losses, net	-4,808	-6,206	-4,114	-3,397
Finance costs, net	233	622	710	1,185
Total non-operating income and expenses	-4,404	-4,584	-3,825	-746
Profit (loss) from continuing operations before tax	-69,073	77,583	46,184	55,498
Total tax expense (income)	29	-1,065	900	-1,547
Profit (loss) from continuing operations	-69,102	78,648	45,284	57,045
Profit (loss)	-69,102	78,648	45,284	57,045
Other comprehensive income				
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	-4,124	119,232	3,785	79,388
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	533	8,654	14	4,806
Components of other comprehensive income that will not be reclassified to profit or loss	-4,657	110,578	3,771	74,582
Total other comprehensive income	-4,657	110,578	3,771	74,582
Total comprehensive income	-73,759	189,226	49,055	131,627
Basic earnings per share				
Total basic earnings per share	-0.45	0.62	0.32	0.45
Diluted earnings per share				
Total diluted earnings per share	-0.45	0.62	0.31	0.45

## Financial Statement – Statements of Cash Flows

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/01/01To2021/06/30	2020/01/01To2020/06/30
<b>Statements of Cash Flows</b>		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	46,184	55,498
Profit (loss) before tax	46,184	55,498
Depreciation expense	69,239	56,040
Amortization expense	8,531	8,105
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	-1,655	3,447
Interest expense	710	1,185
Interest income	-171	-1,324
Share-based payments	6,978	2,423
Loss (gain) on disposal of property, plan and equipment	-36	2,632
Reversal of impairment loss on non-financial assets	-8,512	-562
Other adjustments to reconcile profit (loss)	0	-862
Total adjustments to reconcile profit (loss)	75,084	71,084
Decrease (increase) in contract assets	-53,177	-38,711
Decrease (increase) in accounts receivable	8,342	41,145
Decrease (increase) in accounts receivable due from related parties	-673	924
Decrease (increase) in other receivable	-4,634	1,580
Decrease (increase) in inventories	-63,893	-13,065
Decrease (increase) in prepayments	-20,450	-1,011
Adjustments for decrease (increase) in other current assets	-5,903	3,130
Total changes in operating assets	-140,388	-6,008
Increase (decrease) in contract liabilities	-19,460	-19,894
Increase (decrease) in accounts payable	12,518	6,922
Increase (decrease) in other payable	-3,575	-3,647
Increase (decrease) in other payable to related parties	0	-184
Adjustments for increase (decrease) in other current liabilities	-182	258
Increase (decrease) in net defined benefit liability	-12	-20
Total changes in operating liabilities	-10,711	-16,565
Total changes in operating assets and liabilities	-151,099	-22,573
Total adjustments	-76,015	48,511
Cash inflow (outflow) generated from operations	-29,831	104,009
Interest paid	-1,351	-774
Income taxes refund (paid)	-287	294
Net cash flows from (used in) operating activities	-31,469	103,529
Cash flows from (used in) investing activities		
Proceeds from disposal of financial assets at fair value through other comprehensive income	88,405	2,653
Proceeds from disposal of financial assets at amortised cost	0	75,178
Acquisition of property, plant and equipment	-145,825	-26,008
Proceeds from disposal of property, plant and equipment	180	900
Increase in refundable deposits	-2	-202
Acquisition of intangible assets	-2,150	0
Increase in prepayments for business facilities	-233,684	-26,561
Interest received	158	1,393
Other investing activities	0	-13,100
Net cash flows from (used in) investing activities	-292,918	14,253
Cash flows from (used in) financing activities		
Decrease in short-term loans	-100,000	0
Payments of lease liabilities	-13,956	-7,546
Proceeds from issuing shares	760,594	0
Exercise of employee share options	2,037	0
Net cash flows from (used in) financing activities	648,675	-7,546
Net increase (decrease) in cash and cash equivalents	324,288	110,236
Cash and cash equivalents at beginning of period	291,141	193,671
Cash and cash equivalents at end of period	615,429	303,907
Cash and cash equivalents reported in the statement of financial position	615,429	303,907

Provided by: Mycenax Biotech Inc.  
 Financial year: Yearly  
 Unit: NT\$ thousand

**2021/06/30 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,282,377	499	1,282,876	53,113	-207,233	-207,233	82,911	82,911		1,211,667
Profit (loss)	0	0	0	0	45,284	45,284	0	0		45,284
Other comprehensive income	0	0	0	0	0	0	3,771	3,771		3,771
Total comprehensive income	0	0	0	0	45,284	45,284	3,771	3,771		49,055
Issue of shares	250,000	0	250,000	510,594	0	0	0	0		760,594
Share-based payments	0	0	0	6,978	0	0	0	0		6,978
Disposal of investments in equity instruments designated at fair value through other comprehensive income	0	0	0	0	39,549	39,549	-39,549	-39,549		0
Others	168	1,510	1,678	359	0	0	0	0		2,037
Total increase (decrease) in equity	250,168	1,510	251,678	517,931	84,833	84,833	-35,778	-35,778		818,664
Equity at end of period	1,532,545	2,009	1,534,554	571,044	-122,400	-122,400	47,133	47,133		2,030,331

**2020/06/30 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,279,545	1,279,545	260,908	-473,311	-473,311	34,811	34,811		1,101,953
Capital surplus used to offset accumulated deficits	0	0	-221,400	221,400	221,400	0	0		0
Profit (loss)	0	0	0	57,045	57,045	0	0		57,045
Other comprehensive income	0	0	0	0	0	74,582	74,582		74,582
Total comprehensive income	0	0	0	57,045	57,045	74,582	74,582		131,627
Issue of shares	0	0	0	0	0	0	0		0
Share-based payments	0	0	2,423	0	0	0	0		2,423
Disposal of investments in equity instruments designated at fair value through other comprehensive income	0	0	0	1,113	1,113	-1,113	-1,113		0
Total increase (decrease) in equity	0	0	-218,977	279,558	279,558	73,469	73,469		134,050
Equity at end of period	1,279,545	1,279,545	41,931	-193,753	-193,753	108,280	108,280		1,236,003